CHD5 inhibits metastasis of neuroblastoma

Laut, Astrid K; Dorneburg, Carmen; Fürstberger, Axel; Barth, Thomas F.E.; Kestler, Hans A.; Debatin, Klaus‐Michael; Beltinger, Christian

doi:10.1038/s41388-021-02081-0

Cited by 22 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we first demonstrated that CHD5 was differentially expressed between most cancer tissues and the adjacent normal tissues, which suggested that CHD5 was a potential tumor suppressor gene in most cancers. The above finding was consistent with previously reported results regarding the differential expression of CHD5 in different cancers, including neuroblastoma, melanoma, hepatocellular carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma [ 20 , 21 , 22 , 23 , 24 ]. Our results also showed that the expression of CHD5 was upregulated in some cancer types.…”

Section: Discussionsupporting

confidence: 93%

Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma

Shao

Luo

et al. 2022

IJMS

View full text Add to dashboard Cite

The chromodomain helicase DNA binding domain 5 (CHD5) is required for neural development and plays an important role in the regulation of gene expression. Although CHD5 exerts a broad tumor suppressor effect in many tumor types, its specific functions regarding its expression levels, and impact on immune cell infiltration, proliferation and migration in glioma remain unclear. Here, we evaluated the role of CHD5 in tumor immunity in a pan-cancer multi-database using the R language. The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), and Cancer Cell Lines Encyclopedia (CCLE) datasets were utilized to determine the role of CHD5 in 33 types of cancers, including the expression level, prognosis, tumor progression, and immune microenvironment. Furthermore, we explored the effect of CHD5 on glioma proliferation and migration using the cell counting kit 8 (CCK-8) assay, transwell assays and western blot analysis. The findings from our pan-cancer analysis showed that CHD5 was differentially expressed in the tumor tissues as compared to the normal tissues. Survival analysis showed that CHD5 was generally associated with the prognosis of glioblastoma (GBM), low Grade Glioma (LGG) and neuroblastoma, where the low expression of CHD5 was associated with a worse prognosis in glioma patients. Then, we confirmed that the expression level of CHD5 was associated with tumor immune infiltration and tumor microenvironment, especially in glioma. Moreover, si-RNA mediated knockdown of CHD5 promoted the proliferation and migration of glioma cells in vitro. In conclusion, CHD5 was found to be differentially expressed in the pan-cancer analysis and might play an important role in antitumor immunity. CHD5 is expected to be a potential tumor prognostic marker, especially in glioma.

show abstract

Section: Discussionsupporting

confidence: 93%

Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma

Shao

Luo

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…A total of 31 upregulated and 37 downregulated genes were identified between the 2 clusters (Figure S1A). Interestingly, the wellknown CHD5 tumor suppressor gene in NB was included in the downregulated genes, which was consistent with a previous study (17). The biological function of DEGs was explored through GO enrichment analysis, which showed synapse organization was an area of significant enrichment for the DEGs (Figure S1B).…”

Section: Exploration Of Cluster Charactersupporting

confidence: 87%

Tumor dormancy is closely related to prognosis prediction and tumor immunity in neuroblastoma

Tian¹,

Cao²,

Li³

et al. 2023

Transl Pediatr

View full text Add to dashboard Cite

Background: Neuroblastoma (NB), which is the most frequent and fatal solid tumor in early childhood, lacks an accurate approach to prevent or forecast its recurrence. Dormant NB cells are responsible for metastasis, drug resistance, and suppressive activity in the immune system. However, there is a lack of systematic research on the interaction between dormancy and NB prognosis and its potential associations with tumor immunity. Methods: We downloaded NB gene expression data and clinical information from the Gene ExpressionOmnibus and ArrayExpres databases. Based on consensus clustering of the expression of dormancyassociated genes, the NB samples were classified into different groups, and differentially expressed genes (DEGs) were explored in each group. Functional analyses of DEGs were performed, followed by the establishment of a predictive dormancy signature and the assessment of tumor immunity. Finally, sex, age, International Neuroblastoma Staging System (INSS) stage, and MYCN status were identified as independent overall survival-related variables, which were incorporated into the nomogram. Results: A dormancy-associated gene signature, including CDKN2A, BHLHB3, CDKN2B, MAPK14, CDKN1B, and BMP7, was established. The gene signature showed a strong correlation with NB immune infiltration and capacity to predict NB patient prognosis. A nomogram including MYCN status, INSS stage, age and gene signature risk score was established which further divided NB into high, medium and low-risk groups. This nomogram had certain guiding significance in decision-making for clinical treatment.Conclusions: Our results suggested that the 6-gene genetic signature for NB based on dormancy could predict NB survival and response to immunotherapy.

show abstract

“…Neuroblastoma is a malignant neuroectodermal tumor that originated from cells of the neural crest and is the most common extracranial solid malignant tumor of childhood [ 1 , 2 ]. About 50% of neuroblastoma patients had metastasis at the time of initial diagnosis, which is frequently associated with unsatisfactory outcomes.…”

Section: Introductionmentioning

confidence: 99%

18F-FDG PET/CT-based radiomics nomogram could predict bone marrow involvement in pediatric neuroblastoma

Feng

Yang

et al. 2022

Insights Imaging

View full text Add to dashboard Cite

Objective To develop and validate an 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT)-based radiomics nomogram for non-invasively prediction of bone marrow involvement (BMI) in pediatric neuroblastoma. Methods A total of 133 patients with neuroblastoma were retrospectively included and randomized into the training set (n = 93) and test set (n = 40). Radiomics features were extracted from both CT and PET images. The radiomics signature was developed. Independent clinical risk factors were identified using the univariate and multivariate logistic regression analyses to construct the clinical model. The clinical-radiomics model, which integrated the radiomics signature and the independent clinical risk factors, was constructed using multivariate logistic regression analysis and finally presented as a radiomics nomogram. The predictive performance of the clinical-radiomics model was evaluated by receiver operating characteristic curves, calibration curves and decision curve analysis (DCA). Results Twenty-five radiomics features were selected to construct the radiomics signature. Age at diagnosis, neuron-specific enolase and vanillylmandelic acid were identified as independent predictors to establish the clinical model. In the training set, the clinical-radiomics model outperformed the radiomics model or clinical model (AUC: 0.924 vs. 0.900, 0.875) in predicting the BMI, which was then confirmed in the test set (AUC: 0.925 vs. 0.893, 0.910). The calibration curve and DCA demonstrated that the radiomics nomogram had a good consistency and clinical utility. Conclusion The 18F-FDG PET/CT-based radiomics nomogram which incorporates radiomics signature and independent clinical risk factors could non-invasively predict BMI in pediatric neuroblastoma.

show abstract

CHD5 inhibits metastasis of neuroblastoma

Cited by 22 publications

References 42 publications

Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma

Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma

Tumor dormancy is closely related to prognosis prediction and tumor immunity in neuroblastoma

18F-FDG PET/CT-based radiomics nomogram could predict bone marrow involvement in pediatric neuroblastoma

Contact Info

Product

Resources

About